IP Library Granted Patent US 7,332,335
Granted Patent B2
US 7,332,335 · App. 10/358,851 · Granted Feb 19, 2008

Decreasing cell proliferation by decreasing levels of PP5

Assignee: South Alabama Medical Science Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,332,335
App. No.
10/358,851
Granted
Feb 19, 2008
Kind
B2
Abstract

The invention provides a method of increasing expression of p21 WAF1/Cip 1 in cells to decrease proliferation of the cells, the method comprising decreasing levels of PP5 protein in the cells. The invention further provides a method of treating or preventing an abnormal condition resulting from a defect in a tumor suppressor gene in a subject that results in decreased induction of p21 WAF1/Cip 1 in the cells of the subject, the method comprising administering to the subject an amount of a compound effective to decrease levels of PP5 protein in the cells of the subject.

Claims (10)

1. A method of activating p53 to increase expression of p21 WAF1/Cip 1 in cells, the method comprising:

selecting cells for decreasing levels of PP5 protein;

exposing the cells to a compound which decreases levels of PP5 protein in cells in vitro, wherein the compound is an antisense oligonucleotide having a nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:8, and SEQ ID NO:9 or an inhibitor of the PP5 protein and;

measuring the levels of PP5 protein in the cells, measuring inhibition of the PP5 protein or measuring proliferation of the cells.

2. The method of claim 1 wherein the inhibitor of the PP5 protein is okadaic acid or microcystin.

3. The method of claim 1 wherein the cells are cancer cells.

4. The method of claim 3 wherein the cancer cells harbor a defect in a tumor suppressor gene that results in decreased induction of p21 WAF1/Cip 1 , wherein the tumor suppressor gene is a p53 gene or a BRCA1 gene.

5. A method of treating a subject having a defect in a tumor suppressor gene the method comprising:

selecting a subject having cells having a defect in a p53 gene or a BRCA1 gene and in which expression of p21 WAF1/Cip 1 is to be increased and

administering to the subject a compound under conditions effective to activate p53 to increase expression of p21 WAF1/Cip 1 in the cells and decrease levels of PP5 protein in the cells, wherein the compound is an antisense oligonucleotide having a nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:8, and SEQ ID NO:9.

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 23, 2022
From: UNIVERSITY OF SOUTH ALABAMA
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 060863/0998 →
CONFIRMATORY LICENSE Recorded Jun 9, 2016
From: UNIVERSITY OF SOUTH ALABAMA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 038943/0034 →
Continuity (1)
Related Publication 20030220279A1 · Nov 27, 2003